May 15
|
Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee
|
Apr 21
|
DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders
|
Apr 17
|
Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders
|
Apr 15
|
Is Pacira BioSciences, Inc. (PCRX) the Best Pharma Stock to Buy for Long Term Growth?
|
Apr 11
|
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
Apr 10
|
The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb
|
Apr 9
|
Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More
|
Apr 9
|
Pacira price target raised to $28 from $25 at Truist
|
Apr 8
|
PCRX Stock Soars on Exparel Patent Settlement With Generic Players
|
Apr 7
|
Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL
|
Mar 14
|
Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual
|
Mar 14
|
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences
|
Feb 20
|
Why Pacira (PCRX) is a Top Momentum Stock for the Long-Term
|
Feb 20
|
Pacira to Report 2024 Financial Results on Thursday February 27, 2025
|
Feb 11
|
Best Value Stocks to Buy for February 11th
|
Jan 2
|
Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
|
Sep 26
|
Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
|
Sep 25
|
DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders
|
Jul 30
|
Pacira: Q2 Earnings Snapshot
|
Jul 30
|
Pacira BioSciences Reports Second Quarter 2024 Financial Results
|